http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Sang Hoon Lee,Moon Jae Chung Korean Society of Gastrointestinal Cancer 2014 Journal of digestive cancer reports Vol.2 No.1
We report a patient with combined hepatocellular-cholangiocarcinoma confined in the common hepatic duct and scirrhous type of hepatocellular carcinoma in the caudate lobe of liver simultaneously. The patient was a 55-yearsold Korean man with hepatitis B virus (HBV) carrier who was referred from a local hospital due to detected liver mass on abdominal computed tomography (CT). He has presented jaundice and weight loss for the previous 3 weeks. Laboratory examination showed AST/ALT elevation and hyperbilirubinemia. HBsAg was positive. The tumor marker study showed elevated AFP and DCP, not CEA and CA 19-9. Abdominal CT disclosed an about 2.1×0.9 cm sized soft tissue density in hilum with both intrahepatic duct (IHD) dilatations and an about 3×2.1 cm sized arterial enhancing lesion at segment 8 of the liver. Patient received 15 cycles of Gemcitabine/Cisplantin chemotherapy from February 27, 2013 to December 31, 2013. Caudate lobectomy of liver, segmental resection of bile duct and Roux-en-Y hepaticojejunostomy was performed on February 10, 2014. The final pathologic report showed double primary liver cancer, combined hepatocellular-cholangiocarcinoma in common hepatic bile duct and scirrhous type of hepatocellular carcinoma in segment 1 of the liver. This is a very unusual case in which combined hepatocellular-cholangiocarcinoma confined in the large bile duct and two rare hepatic cancers coexisted.
김재희,이용구,이준,정철권,김형태,강혜윤,고광현,홍성표,황성규,박필원,임규성 대한간학회 2004 Clinical and Molecular Hepatology(대한간학회지) Vol.10 No.2
Combined hepatocellular-cholangiocarcinoma is a rare form of primary liver cancer, featuring both hepatocellular and biliary epithelial differentiations. An intrahepatic tumor may be considered as a metastatic lesion. It has been suggested in the literature that the likelihood of metastasis in the cirrhotic liver is lower than that in the non-cirrhotic liver. A rare case of combined hepatocellular-cholangiocarcinoma and second primary colon adenocarcinoma in a 67-year-old male patient with liver cirrhosis is presented. Histologically, the intrahepatic mass was composed of a spindle cell sarcomatous component; a hepatocellular carcinoma component; and a cholangiocarcinoma component. There were focal transitional regions among the different components. Immunohistochemically, the cholangiocarcinoma component of the intrahepatic mass showed positive reaction for CK-7 but negative reactions for CK-20. The adenocarcinoma of the colon showed positive reactions for CK-20 but negative reactions for CK-7. (Korean J Hepatol 2004;10:142-147)
박하나,박준용,최기홍,최새별,최종원,김도영,안상훈,김경식,최진섭,한광협,전재윤 연세대학교의과대학 2011 Yonsei medical journal Vol.52 No.5
Purpose: Combined hepatocellular-cholangiocarcinoma (CHCC) is an uncommon form of cancer, and its clinicopathological features have rarely been reported in detail. This study was undertaken to evaluate the clinicopathological characteristics and prognostic factors of CHCC. Materials and Methods: The clinicopathological features of patients diagnosed with CHCC at Severance Hospital between January 1996 and December 2007 were retrospectively studied by comparing them with the features of patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) who had undergone a hepatic resection during the same period. Results: Forty-three patients diagnosed with CHCC were included in this study (M : F=35 : 8, median age, 55 years). According to the parameters of the American Joint Committee on Cancer staging, there were 6 (14.0%), 9 (20.9%), 25 (58.1%), and 3 (7.0%) patients with stages I, II, III, and IV cancer, respectively. Thirty-two of the 43 patients underwent resection with curative intent. After resection, 27 patients (84.4%) had tumor recurrence during the follow-up period of 18 months (range: 6-106 months), and the median time to recurrence was 13 months. Overall median survival periods after hepatic resection of CHCC, HCC and CC were 34, 103 and 38.9 months, respectively (p<0.001). The median overall survival for all patients with CHCC was 21 months, and the 5-year survival rate was 18.1%. The presence of portal vein thrombosis and distant metastasis were independent prognostic factors of poor survival. Conclusion: Even after curative hepatic resection, the presence of a cholangiocellular component appeared to be a poor prognostic indicator in patients with primary liver cancer.
Hai-Chun Zhang,Ting Zhu,Rong-Fei Hu,Long Wu 대한초음파의학회 2020 ULTRASONOGRAPHY Vol.39 No.4
Purpose: The purpose of this study was to retrospectively compare the clinical characteristics and imaging features on (CEUS) of combined hepatocellular cholangiocarcinoma (CHC) with those of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Methods: The clinical information and CEUS features of 45 patients with CHC from 2015 to 2019 and 1-to-1-matched control subjects with HCC and CC (45 each) were compared. Results: Simultaneous elevation of α-fetoprotein (AFP) and cancer antigen (CA) 19-9 was more common in CHC than in HCC and CC. In the arterial phase, hyperenhancement (homogeneous and heterogeneous) was more common in CHC (73.3%) and HCC (100%), while peripheral rim-like enhancement was more common in CC (55.6%). In the portal phase, marked washout was significantly more frequent in CHC and CC than in HCC (42.2% and 53.3% vs. 6.7%). In the delayed phase, marked washout was more common in CHC (82.2%) and CC (93.3%) than in HCC (40.0%). The washout time (WT) was much shorter in CHC and CC than in HCC (33.8±13.1 seconds and 30.1±11.6 seconds vs. 58.4±23.5 seconds). Using the combination of simultaneous elevation of AFP and CA 19-9 with marked washout in the delayed phase and a WT <38 seconds or arterial hyperenhancement to differentiate CHC from HCC or CC, the accuracy, sensitivity, and specificity were 74.4%, 93.3%, and 55.6% and 71.1%, 80.0%, and 62.2%, respectively. Conclusion: Although some CEUS imaging features of CHC, HCC, and CC overlap, the combination of tumor markers and CEUS features can be helpful in differentiating CHC from HCC and CC.
선행항암화학요법 후 근치적 절제한 진행성 혼합 간세포-담관암종 1예
최지은 ( Jee Eun Choi ),김경희 ( Kyung Hee Kim ),김선아 ( Seon A Kim ),이정환 ( Jung Hwan Lee ),우상명 ( Sang Myung Woo ),박상재 ( Sang Jae Park ),홍은경 ( Eun Kyung Hong ),이우진 ( Woo Jin Lee ) 대한췌담도학회 2016 대한췌담도학회지 Vol.21 No.2
혼합 간세포-담관암종은 조직학적 특성이 다양한 원발성 간암의 드문 형태이다. 혼합 간세포-담관암종의 근치적 치료법은 수술적 절제가 유일하나, 진행성 혼합 간세포-담관암종의 치료에 대해서는 잘 정립되어 있지 않다. 저자들은 진행성 혼합 간세포-담관암종에서 선행항암화학요법을 시행 후 근치적 수술이 가능하였고, 수술 15개월 후까지 재발을 보이지 않은 증례를 보고하는 바이다. Combined hepatocellular-cholangiocarcinoma (HCC-CC) is a primary liver cancer with histopathologic features of both hepatocelluar carcinoma and cholangiocarcinoma. As combined HCC-CC has been associated with poor outcomes, accurate diagnosis and proper treatment planning for patients are considered to be important for improving survival. Currently, surgery is known as the only treatment modality offering potential cure for localized disease. However, there are little published treatment options for advanced or recurrent disease. Furthermore, no published reports exist in respect to the applying successful curative resection after neoadjuvant therapy for advanced combined HCC-CC. Here, we report a case of combined HCC-CC subtype with stem cell feature, intermediate type who underwent curative surgical resection after neoadjuvant chemotherapy consisting of cisplatin and gemcitabine. Pathologic report revealed negative resection margin and follow-up imaging study shows no evidence of tumor recurrence.
백승석 ( Seung Suk Baek ),윤아일린 ( Eileen L. Yoon ),김현정 ( Hyun-jung Kim ),배경은 ( Kyung Eun Bae ),박경미 ( Kyeongmee Park ),최원충 ( Won-choong Choi ) 대한간암학회 2017 대한간암학회지 Vol.17 No.2
Heterogeneous features of liver cancer can mimic liver abscess. Therefore it is essential to double- check tumor markers in the diagnosis of liver abscess. Herein, we report a case of combined hepatocellular-cholangiocarcinoma (cHC) occurred in an unrecognized chronic hepatitis B patient initially misdiagnosed as liver abscess. A 49-year old male initially presented with chill, right upper quadrant pain, and a liver mass. Mass showed peripheral enhancement in arterial phase of computed tomography, which was not typical for hepatocellular carcinoma (HCC). Strikingly elevated alpha-fetoprotein and fine needle aspirated pathology revealed HCC. Despite discordant image findings he was treated with transarterial chemoembolization. He was treated with sorafenib due to metastatic retrocaval lymphadenopathy afterwards. The mass presumed to be HCC progressed with sorafenib. It was surgically resected and he was finally confirmed as cHC. Discordant tumor markers with presumptive image findings should prompt the suspicion of rare type of primary liver cancer, the cHC. (J Liver Cancer 2017;17:174-181)
( Seong Kyun Na ),( Han Chu Lee ),( Gwang Hyeon Choi ),( Jihyun An ),( Dan Bi Lee ),( Ju Hyun Shim ),( Kang Mo Kim ),( Young-suk Lim ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Combined HCC-CC (cHCC-CC) is presented as hypervascular tumor or peripheral enhancing tumor in dynamic CT scan. We evaluated the effect of transarterial chemoembolization (TACE) and prognosis according to the post-operative recurrence imaging patterns of cHCC-CC. Methods: We retrospectively analyzed 43 cHCC-CC patients who were treated with TACE for 1<sup>st</sup> post-operative recurrence after curative surgical resection between January 2000 and May 2016 and 59 hepatocellular carcinoma (HCC) patients between January 2008 and June 2008 at Asan Medical Center in Korea. Tumor with arterial enhancement more than 50% of tumor volume in CT was classified as hypervascular tumor, in contrast, tumor with peripheral enhancement were classified as peripheral enhancing tumor. Tumor responses were evaluated according to RECIST 1.1 criteria. Results: The median follow up duration was 53.5 months (interquartile range: 23.2 - 101.8 months). In cHCC-CC group, primary hypervascular and peripheral enhancing tumor were in 19 patients and 24 patients. Hypervascular recurred tumor and peripheral enhancement recurred tumor were in 26 patients and 17 patients. Agreement of imaging patterns between primary tumor and recurred tumor was 78.9% in hypervascular tumor, and 54.2% in peripheral enhancement tumor. After TACE, disease control rate was 84.7% in HCC, 88.5% in hypervascular recurred tumor, and 58.8% in peripheral enhancing recurred tumor (P-value = 0.034). The median survival time after recurrence for HCC was 67.5 months (95% CI 34.5 - 100.6 months) and 52.8 months (95% CI 6.4 - 99.2 months) for hypervascular recurred tumor and 12.4 months (95% CI 8.5 - 16.3 months) for peripheral enhancement recurred tumor (P-value < 0.001). In multivariable Cox regression, peripheral enhancing recurred tumor (HR 3.827, 95% CI 1.544 - 9.489, P-value = 0.004), progressive disease after TACE (HR 3.099, 95% CI 1.208 - 7.950, P-value = 0.019), and recurred tumor size > 2 cm (HR 2.882, 95% CI 1.250 - 2.644, P-value = 0.013) were significant prognostic factors. Conclusions: Recurred cHCC-CC with peripheral enhancement showed poor tumor response for TACE and poor prognosis after recurrence than hypervascular recurred tumor.